Celltrion Calls For Harmonized Approach To ‘Biobetters’
As Latest Data Shows Benefits Of Subcutaneous Infliximab Biosimilar Remsima SC
A standardized, globally-accepted approach to ‘biobetters’ – biosimilars that offer improvements over the original reference drug – is needed to reduce trial duplication and allow products to come to market more quickly, Celltrion tells Generics Bulletin, at the same time as the company published data showing the benefits of its Remsima SC unique subcutaneous formulation of infliximab.
